REAL-WORLD EFFECTIVENESS OF BRENTUXIMAB VEDOTIN VS OTHER TREATMENTS IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA POST AUTOLOGOUS STEM-CELL TRANSPLANTATION

被引：0
|
作者：
Zagadailov, E. A. [1 ]
Corman, S. [2 ]
Hagan, M. [3 ]
Chirikov, V. [2 ]
Johnson, C. [2 ]
Macahilig, C. [3 ]
Sea, B. [1 ]
Dalal, M. R. [1 ]
Broeckelmann, P. J. [4 ,5 ]
Illidge, T. [6 ]
机构：
[1] Millennium Pharmaceut Inc, Cambridge, MA USA
[2] Pharmerit Int, Bethesda, MD USA
[3] Med Data Analyt, Parsippany, NJ USA
[4] Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany
[5] Univ Hosp Cologne, GHSG, Cologne, Germany
[6] Univ Manchester, Inst Canc Sci, Christie Hosp, Manchester, Lancs, England
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P094
引用
收藏
页码：51 / 51
页数：1
相关论文
共 50 条
  • [1] REAL-WORLD EFFECTIVENESS OF BRENTUXIMAB VEDOTIN (BV) VS OTHER TREATMENTS IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA (RRHL) POST AUTOLOGOUS STEM-CELL TRANSPLANTATION (ASCT)
    Zagadailov, E. A.
    Corman, S.
    Hagan, M.
    Chirikov, V.
    Johnson, C.
    Macahilig, C.
    Dalal, M. R.
    Broeckelmann, P. J.
    [J]. HAEMATOLOGICA, 2016, 101 : 98 - 99
  • [2] Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma
    Herrera, A. F.
    Palmer, J.
    Martin, P.
    Armenian, S.
    Tsai, N-C
    Kennedy, N.
    Sahebi, F.
    Cao, T.
    Budde, L. E.
    Mei, M.
    Siddiqi, T.
    Popplewell, L.
    Rosen, S. T.
    Kwak, L. W.
    Nademanee, A.
    Forman, S. J.
    Chen, R.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 (03) : 724 - 730
  • [3] Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation
    Kaloyannidis, Panayotis
    Hertzberg, Mark
    Webb, Kate
    Zomas, Athanasios
    Schrover, Rudolf
    Hurst, Michael
    Jacob, Ian
    Nikoglou, Thalia
    Connors, Joseph M.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2020, 188 (04) : 540 - 549
  • [4] Real-world effectiveness of brentuximab vedotin versus physicians' choice chemotherapy in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplantation in the United Kingdom and Germany
    Zagadailov, Erin A.
    Corman, Shelby
    Chirikov, Viktor
    Johnson, Courtney
    Macahilig, Cynthia
    Seal, Brian
    Dalal, Mehul R.
    Broeckelmann, Paul J.
    Illidge, Tim
    [J]. LEUKEMIA & LYMPHOMA, 2018, 59 (06) : 1413 - 1419
  • [5] Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma
    Pinczes, Laszlo Imre
    Szabo, Roxana
    Illes, Arpad
    Foldeak, Dora
    Piukovics, Klara
    Szomor, Arpad
    Gopcsa, Laszlo
    Miltenyi, Zsofia
    [J]. ANNALS OF HEMATOLOGY, 2020, 99 (10) : 2385 - 2392
  • [6] Improved survival of autologous stem cell transplantation in primary refractory and relapsed Hodgkin lymphoma in the brentuximab vedotin era - real-world data from Hungary
    Husi, Kata
    Szabo, Roxana
    Pinczes, Laszlo Imre
    Foldeak, Dora
    Dudley, Reka
    Szomor, Arpad
    Koller, Beata
    Gopcsa, Laszlo
    Illes, Arpad
    Miltenyi, Zsofia
    [J]. ANNALS OF HEMATOLOGY, 2023, 102 (09) : 2555 - 2563
  • [7] Improved survival of autologous stem cell transplantation in primary refractory and relapsed Hodgkin lymphoma in the brentuximab vedotin era — real-world data from Hungary
    Kata Husi
    Roxána Szabó
    László Imre Pinczés
    Dóra Földeák
    Réka Dudley
    Árpád Szomor
    Beáta Koller
    László Gopcsa
    Árpád Illés
    Zsófia Miltényi
    [J]. Annals of Hematology, 2023, 102 : 2555 - 2563
  • [8] Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma
    László Imre Pinczés
    Roxána Szabó
    Árpád Illés
    Dóra Földeák
    Klára Piukovics
    Árpád Szomor
    László Gopcsa
    Zsófia Miltényi
    [J]. Annals of Hematology, 2020, 99 : 2385 - 2392
  • [9] Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed/refractory Hodgkin lymphoma
    Forlenza, Christopher J.
    Rosenzweig, Jaclyn
    Mauguen, Audrey
    Buhtoiarov, Ilia
    Cuglievan, Branko
    Dave, Hema
    Deyell, Rebecca J.
    Flerlage, Jamie E.
    Franklin, Anna K.
    Krajewski, Jennifer
    Leger, Kasey J.
    Marks, Lianna J.
    Norris, Robin E.
    Pacheco, Martha
    Willen, Faye
    Yan, Adam Paul
    Harker-Murray, Paul D.
    Giulino-Roth, Lisa
    [J]. BLOOD ADVANCES, 2023, 7 (13) : 3225 - 3231
  • [10] Brentuximab Vedotin As Consolidation Therapy Post Hematopoietic Stem Cell Transplantation for Patients with Relapsed or Refractory Hodgkin Lymphoma: A Real World Analysis of the Colombian Experience
    Patino, Bonell
    Acon-Solano, Cristina
    Pereira, Mario
    Enciso-Olivera, Leonardo
    Otero-de la Hoz, Diana
    Cordero, Humberto Martinez
    Spirko, Paola
    Solano-Vega, Julio
    Arevalo-Zambrano, Monica
    Heider, Ulrike
    Ruiz-Patino, Alejandro
    Sossa, Claudia Lucia
    Pena, Angela Maria
    Chalela, Claudia Marcela
    Karduss, Amado
    Leon-Basantes, Guillermo
    Abello, Virginia
    Espinosa, Daniel Lorenzo
    Guerrero, Paola
    Guerrero, Alvaro
    Herrera, Juan Manuel
    Osuna, Monica
    Perdomo, Ivan
    Rosales, Carmen
    Omana, Paola
    Villarroya, Natalia
    Rodriguez-Sanjuan, Victor
    Sandoval-Sus, Jose
    [J]. BLOOD, 2019, 134
12345